Expertise in
2
conditions

Dr. Chad Miller

Family Medicine
Kaiser Permanente Skyline Pharmacy
1375 E 20th Ave, 
Denver, CO 
Expertise in
2
conditions
Kaiser Permanente Skyline Pharmacy
1375 E 20th Ave, 
Denver, CO 

Overview

Chad Miller is a primary care provider, practicing in Family Medicine in Denver, Colorado. Dr. Miller is highly rated in 2 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Hypertension, Cardiomyopathy, and Dilated Cardiomyopathy (DCM).

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Family Medicine

Licenses

General Practice in CO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Kaiser Permanente Skyline Pharmacy
1375 E 20th Ave, Denver, CO 80205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: Intravenous/Subcutaneous Treprostinil
Study Phase: Phase 4
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

15 Total Publications

Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review.
Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review.
Journal: Advances in therapy
Published: October 29, 2025
Similar Doctors
Expertise in
59
conditions
Dr. Danielle Whitacre
Family Medicine
Expertise in
59
conditions
Dr. Danielle Whitacre
Family Medicine

Bloom Healthcare

10900 W 44th Ave Unit 200, 
Wheat Ridge, CO 
 (8.2 miles away)
303-284-4082
Languages Spoken:
English
See accepted insurances

Danielle Whitacre is a primary care provider, practicing in Family Medicine in Wheat Ridge, Colorado. Dr. Whitacre is highly rated in 59 conditions, according to our data. Her top areas of expertise are Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A), Mucopolysaccharidosis Type 3B (MPS IIIB, Sanfilippo Syndrome B), and Apparent Mineralocorticoid Excess.

Expertise in
4
conditions
Dr. Joerg Skomrock
Family Medicine
Expertise in
4
conditions
Dr. Joerg Skomrock
Family Medicine

Denver Wound Healing Center

1719 E 19th Ave, 
Denver, CO 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances

Joerg Skomrock is a primary care provider, practicing in Family Medicine in Denver, Colorado. Dr. Skomrock is highly rated in 4 conditions, according to our data. His top areas of expertise are Peptic Ulcer, Necrosis, Cellulitis, and Stasis Dermatitis and Ulcers.

Expertise in
15
conditions
Dr. Jeremy A. Dubin
Family Medicine
Expertise in
15
conditions
Dr. Jeremy A. Dubin
Family Medicine
3320 W Eisenhower Blvd, 
Loveland, CO 
 (46.3 miles away)
970-669-2849
Languages Spoken:
English
See accepted insurances

Jeremy Dubin is a primary care provider, practicing in Family Medicine in Loveland, Colorado. Dr. Dubin is highly rated in 15 conditions, according to our data. His top areas of expertise are Osteolysis Syndrome Recessive, Opioid Use Disorder, Mesenteric Venous Thrombosis, Hip Replacement, and Knee Replacement.

Frequently Asked Questions about Dr. Chad Miller

How do I make an appointment with Dr. Chad Miller?

You can book an appointment with Dr. Chad Miller by calling their office at 303-764-4507. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chad Miller a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chad Miller is classified as an Advanced expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chad Miller specialize in?

While Dr. Chad Miller is a Family Medicine, they have specific expertise in Pulmonary Hypertension, Hypertension, and Cardiomyopathy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Chad Miller participate in research or clinical trials?

Yes. Dr. Chad Miller has published 15 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Chad Miller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Miller's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile